Genmab A/S (NASDAQ:GMAB) Raised to Reduce at AlphaValue

AlphaValue upgraded shares of Genmab A/S (NASDAQ:GMABGet Rating) to a reduce rating in a report published on Thursday morning, The Fly reports.

Several other analysts have also commented on GMAB. Cowen increased their price target on shares of Genmab A/S to $43.00 in a research report on Tuesday, November 15th. JPMorgan Chase & Co. increased their price objective on shares of Genmab A/S from 2,900.00 to 3,450.00 and gave the company an overweight rating in a research report on Monday, November 14th. SVB Leerink increased their price objective on shares of Genmab A/S to $33.00 and gave the company a market perform rating in a research report on Thursday, November 10th. TheStreet raised shares of Genmab A/S from a c+ rating to a b rating in a research report on Wednesday, August 31st. Finally, Morgan Stanley raised their price target on shares of Genmab A/S from $29.00 to $31.00 and gave the stock an underweight rating in a research report on Monday, August 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of Hold and a consensus target price of $607.12.

Genmab A/S Stock Performance

GMAB stock opened at $43.55 on Thursday. The firm has a market cap of $28.67 billion, a price-to-earnings ratio of 35.70, a PEG ratio of 1.28 and a beta of 0.94. The firm has a 50-day simple moving average of $37.24 and a two-hundred day simple moving average of $34.48. Genmab A/S has a one year low of $26.19 and a one year high of $43.88.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Comerica Bank grew its stake in Genmab A/S by 3.8% in the 1st quarter. Comerica Bank now owns 17,313 shares of the company’s stock valued at $658,000 after acquiring an additional 636 shares during the period. SG Americas Securities LLC grew its stake in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company’s stock valued at $219,000 after acquiring an additional 513 shares during the period. FDx Advisors Inc. grew its stake in Genmab A/S by 9.4% in the 1st quarter. FDx Advisors Inc. now owns 30,087 shares of the company’s stock valued at $1,089,000 after acquiring an additional 2,580 shares during the period. Lester Murray Antman dba SimplyRich grew its stake in Genmab A/S by 1.5% in the 1st quarter. Lester Murray Antman dba SimplyRich now owns 50,044 shares of the company’s stock valued at $1,810,000 after acquiring an additional 733 shares during the period. Finally, Aigen Investment Management LP acquired a new stake in Genmab A/S in the 1st quarter valued at $294,000. Institutional investors and hedge funds own 5.51% of the company’s stock.

About Genmab A/S

(Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

The Fly logo

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.